The QualityStocks Daily Wednesday, April 24th, 2019

Today's Top 3 Investment Newsletters

QualityStocks (NUSMF) +50.00%

InvestorPlace (PIR) +35.56%

StockMarketWatch (TRK) +33.07%

The QualityStocks Daily Stock List

Where Food Comes From, Inc. (WFCF)

NetworkNewsWire, Zacks, Stockhouse, Morningstar, Equity Clock, Simply Wall St, InvestorsHub, Market Screener, 4-Traders, Wallet Investor, Marketbeat, Dividend Investor, and Quality Small Caps reported on Where Food Comes From, Inc. (WFCF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Where Food Comes From, Inc. is the most trusted resource for independent, third-party verification of food production practices in North America. The Company, through proprietary technology and patented business processes, supports over 15,000 farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, consumer brands and restaurants with a broad array of value-added services. Where Food Comes From serves beef and pork packers, organic producers and processors, and specialty retail chains. OTCQB-listed, Where Food Comes From has its head office in Castle Rock, Colorado.

The Company provides its solutions via its IMI Global, International Certification Services, Validus Verification Services, SureHarvest, A Bee Organic and Sterling Solutions units. Where Food Comes From solutions are used to verify food claims, optimize production practices and enable food supply chains with analytics and data driven insights. Furthermore, its Where Food Comes From® retail and restaurant labeling program uses web-based customer education tools to connect consumers to the sources of the food they buy, increasing meaningful consumer engagement for the Company's clients.

Where Food Comes From conducts on-site and desk audits to verify that claims made about livestock, crops, and other food products are accurate. The Company also sells hardware; and develops software and provides services related to sustainability measurement and benchmarking, traceability, verification, and certification to the food and agriculture industries.

In December of 2018, Where Food Comes From announced it was named Program Administrator for the new U.S. Hemp Authority™ Certified verification standard. With this agreement, the Company's Validus Verification Services unit was named as exclusive certification body for hemp growers and processors seeking to comply with the standard and earn the right to display the U.S. Hemp Authority™ Certified seal in their product labeling, advertising and marketing.

Last month, Where Food Comes From announced its 2018 Q4 and full year financial results. Mr. John Saunders, Chairman and Chief Executive Officer, said, "We delivered solid financial results for the year, highlighted by revenue up 15 percent to $17.8 million and net income up 463 percent to $801,000. We also generated a record $1.2 million in cash from operations for the year. Our growth was largely attributable to increased verification activity across a range of standards and particularly the area of source verification related to the reopening of China's beef markets."

Where Food Comes From, Inc. (WFCF), closed Wednesday's trading session at $2.04, up 4.62%, on 11,800 volume with 10 trades. The average volume for the last 3 months is 11,033 and the stock's 52-week low/high is $1.75/$2.50.

chart

International Land Alliance, Inc. (ILAL)

OTC Markets, InvestorsHub, Simply Wall St, Investors Hangout, Morningstar, The Street, Trading View, and Market Screener reported previously on International Land Alliance, Inc. (ILAL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

International Land Alliance, Inc. concentrates on the development, construction, and marketing of properties. The Company's inventory includes properties that are residential, commercial, recreational, waterfront, ranch, hotel, and marina. International Land Alliance's shares trade on the OTC Markets Group's OTCQB. Established in 2013, the Company has its corporate headquarters in San Diego, California.

International Land Alliance's intention is to construct and develop resort properties, and other commercial properties, and also residential communities to home buyers, retirees, investors, and commercial developers. The Company's main goal is to sell desirable properties, at competitive prices, with favorable financing options for individual purchases and/or bulk purchases suitable for all kinds of investors and buyers.

International Land Alliance offers the option of financing with a guaranteed acceptance on any purchase for every customer. The Company removes the middleman. As such, loans are approved directly by International Land Alliance providing easy and affordable financing terms. Moreover, there are no prepayment penalties, credit or background checks, and extremely competitively low interest rates.

The Company's developments include Oasis Park Resort; Valle Divino Resort; and Villas Del Enologo (Vintners Villas) at Rancho Tecate. Oasis Park Resort (San Felipe – Puertecitos Corridor Northern Baja California, Mexico) is a 497 acre master planned real estate community just south of San Felipe. It is undergoing development as an ecotourism, green community to coincide with the natural amenities Baja California provides. There are 1,344 residential home sites that are roughly 1/4-acre each.

Valle Divino Resort consists of 123 residential lots and 3 commercial lots comprising a total of 20 acres in Ensenada, Baja, Mexico. Villas Del Enologo at Rancho Tecate is a 2.6 acre parcel within the prestigious Rancho Tecate. It is a planned 24 – 2B/2B Vineyard Villas with private wine cellar.

The Second Phase will include an additional 22 Vineyard Villas. The Rancho Tecate Resort is a 1,500-acre master planned resort in Tecate, Baja California, situated 7 miles south of the U.S.-Mexico Border and just north of the Guadalupe Valley, the premier wine region in all of Mexico. The Rancho Tecate Resort includes 1,400 home sites, a renowned restaurant, a hotel with conference facilities, and equestrian – all surrounding a verdant vineyard landscape.

International Land Alliance, Inc. (ILAL), closed Wednesday's trading session at $2.50, up 25.00%, on 1,300 volume with 7 trades. The average volume for the last 3 months is 1,700 and the stock's 52-week low/high is $0.50/$5.00.

chart

Bonterra Resources, Inc. (BONXF)

Investing News, Streetwise Reports, Proactive Investors, Wallet Investor, Research Pool, YCharts, Canadian Insider, Stockhouse, Mining Capital, OTC Markets, Capital Cube, The Prospector News, Investors Hangout, Mining and Energy, Junior Mining Network, InvestorsHub, and Barchart reported previously on Bonterra Resources, Inc. (BONXF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Bonterra Resources, Inc. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. The Company has a large balanced portfolio of exploration and mining assets. These include the Gladiator, Barry and Moroy deposits, Urban-Barry Mill and multiple highly prospective exploration prospects. Bonterra Resources lists on the OTC Markets' OTCQX. The Company has a strong shareholder base that includes Wexford Capital, Kirkland Lake Gold, and Eric Sprott. Bonterra Resources is headquartered in Val-d'Or, Quebec.

Presently, Bonterra is developing three high-grade gold deposits: the Gladiator, Barry and Moroy projects in the mining-friendly jurisdiction of Quebec. There are significant regional targets in the Urban Barry Camp. The Company is in the process of upgrading its wholly-owned gold mill to boost capacity from 800 to 2400 tpd. In addition, a property-wide mineral resource estimate is taking place and will include the Gladiator, Barry and Moroy deposits. Bonterra Resources controls the only permitted gold mill in the region with a large land position of roughly 20,815 hectares in the Urban Barry Camp.

Earlier this month, Bonterra Resources announced assay results from its continuing diamond drilling program at its Gladiator Project positioned in the Urban Barry exploration camp in northern Quebec. The results reported extend a number of the gold-bearing mineralized zones along strike on the Gladiator Deposit.

Regarding the Barbeau zone, current drilling has extended the zone by 250 meters, confirming its continuity in grade and length with hole BA-19-24, which returned 14.6 g/t Au over 4.6 m. The Barbeau zone has now been outlined over a strike length of 450 meters to a depth of 200 meters.

The Rivage 2 zone is positioned north of the Gladiator deposit. Initially discovered by field prospecting in the summer of 2018, the mineralized zone now extends more than 350 meters to a depth of 200 meters. Drill hole BA-19-28 returned 37.6 g/t Au over 1.7 m. The Rivage 2 zone remains open along strike and at depth.

The South zone is in the heart of the Gladiator deposit. It was intersected in drill hole BA-19-26A, which returned 17.7 g/t Au over 2.0 m. Mineralization usually comprises smoky quartz, pyrite, sphalerite and visible gold. Attesting to Bonterra Resources' geological modeling and continuity of the mineralized zones, this drill hole was expected to intersect the South zone before reaching the Barbeau zone.

Bonterra Resources, Inc. (BONXF), closed Wednesday's trading session at $1.22, up 6.77%, on 14,543 volume with 19 trades. The average volume for the last 3 months is 18,238 and the stock's 52-week low/high is $0.223/$2.869.

chart

Dthera Sciences (DTHR)

NetworkNewsWire, Internet Bull Report, Stockopedia, PR Newswire, Stockhouse, Trial Site News, InvestorsHub, Accesswire, Investors Hangout, Stockwatch, Wallet Investor, Market Screener, Dividend Investor, and Trading View reported earlier on Dthera Sciences (DTHR), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Dthera Sciences is the leading digital therapeutic company focusing on the elderly. It specializes in neurodegenerative diseases. The Company is working to improve the lives of seniors and individuals suffering from neurodegenerative diseases, and also those who care for them. Dthera is developing DTHR-ALZ, a medical device. Dthera Sciences' shares trade on the OTCQB. The Company is based in San Diego, California.

In December 2018, Dthera Sciences announced that the U.S. Food and Drug Administration (FDA) informed Dthera that it believes that a De Novo submission is the most suitable regulatory pathway for DTHR-ALZ, as Dthera Sciences had proposed. DTHR-ALZ is a medical device that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer's disease. If granted clearance by the FDA, DTHR-ALZ would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer's disease.

The DTHR-ALZ device digitally delivers an evidence-based behavioral intervention called Reminiscence Therapy to individuals with Alzheimer's disease. DTHR-ALZ is not yet cleared by the U.S. Food and Drug Administration (FDA), and is not yet available for commercial use in the United States.

DTHR-ALZ consists of three key components. One is a custom computer tablet specifically designed and tested for seniors with Alzheimer's disease. The second is a facial expression detection system to assess the reaction to reminiscence content. The third component is a two sided AI that obtains and optimizes therapeutic content being delivered to the patient.

Recently, Dthera Sciences announced that it entered into an exclusivity agreement with a company based in Japan for development and commercialization rights to Dthera's lead product, DTHR-ALZ. The exclusivity agreement provides exclusive rights to the Japanese partner to perform feasibility studies in Japan and to negotiate a licensing agreement or other transaction for the Japanese market during the agreed term. In consideration for the exclusive review and negotiation period, the Japanese partner has paid Dthera Sciences a non-refundable cash payment.

Earlier this month, Dthera Sciences announced that its Board of Directors began a process to pursue a range of potential strategic transactions to enable Dthera to bring its development-stage Alzheimer's product, DTHR-ALZ, to market faster. These structures include a funded partnership on DTHR-ALZ, an acquisition of Dthera Sciences, a business combination, or strategic investment/financing into the Company.

Dthera Sciences has been in early-stage discussions with a number of third-party entities relating to a licensing partnership or acquisition. The Company has also been approached regarding business combination transactions. Dthera has elected to formalize the process by announcing its goal of finding a commercialization partner.

Dthera Sciences (DTHR), closed Wednesday's trading session at $3.00, up 38.89%, on 100 volume with 1 trade. The average volume for the last 3 months is 663 and the stock's 52-week low/high is $2.09/$16.79.

chart

Petrogress, Inc. (PGAS)

NetworkNewsWire, Marketbeat, Last10k, MarketWatch, Whale Wisdom, OilandGas360, Trading View, Investors Hangout, Stockhouse, Stockwatch, StockInvest, Barchart, 4-Traders, YCharts, Wallet Investor, Simply Wall St, GuruFocus, Stockopedia, and Dividend Investor reported earlier on Petrogress, Inc. (PGAS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Petrogress, Inc., by way of its subsidiaries, operates as an integrated merchant of petroleum products. The Company is an independent Oil energy and Shipping company. It specializes in oil exploration, production, trade and sea transportation with global operations throughout Europe, Africa and the Middle East. The Company owns and operates a fleet of tankers from its base in the historic Port of Piraeus through a series of Marshall Islands subsidiaries. Petrogress is based in Delaware and New York and lists on the OTC Markets.

The Company operates mainly as a holding company for its wholly-owned subsidiaries. Petrogress concentrates on the supply and trade of light petroleum fuel oil, refined oil products and other petrochemical products to local refineries in West Africa and Mediterranean countries.

In addition, Petrogress operates service and shipping facilities at the Port of Limassol in Cyprus and the Port of Tema, Greater Accra, in Ghana. The Company is actively looking for expansion opportunities. This includes in operating and developing natural gas production and transmission facilities along with LNG processing in the United States, refinery operations in north and West Africa, and the transport and sales of LNG in Europe.

For Upstream - oil resources and exploration, Petrogress has its Petrogres Oil & Gas Energy, Inc. subsidiary. For Midstream - product fleet carriers, the Company has its Petronav Carries, LLC subsidiary. Regarding Downstream – processing and refining, it has its J/V PGO & PGL – Ghana subsidiary. Furthermore, regarding Marketing – purchases and sales, Petrogress has its Petrogres Co. Limited subsidiary.

In December of 2018, Petrogress announced that its Petrogress Int'l, LLC (PIL) subsidiary entered into a Partnership Agreement with Deliman Oil Company Limited, a Ghanaian corporation. This Agreement is to jointly create and co-operate a Ghanaian corporation to be called PG&D Fueling. PG&D will operate and manage gas/refueling stations in Ghana, Burkina Faso and Niger and associated storage and distribution operations.

The expectation is that PG&D will initially operate and manage 65 gas stations now owned by Deliman in Ghana and Burkina Faso. The petrochemical products to be distributed via PG&D managed gas stations will be supplied by PIL affiliate company Petrogres Co. Limited, via its partnership with Platon Oil Refinery in Ghana.

Last month, Petrogress announced that its PIL subsidiary entered into an Exclusive Distribution Agreement with Dana Lubricants Factory LLC (Dana Lubes), a United Arab Emirates (UAE) based lubricant oil manufacturer. This agreement designates PIL as the exclusive agent for distribution of products manufactured and branded by Dana Lubes throughout western Africa.

Petrogress, Inc. (PGAS), closed Wednesday's trading session at $2.02, up 7.16%, on 400 volume with 1 trade. The average volume for the last 3 months is 2,539 and the stock's 52-week low/high is $0.006/$2.09.

chart

Relmada Therapeutics, Inc. (RLMD)

NetworkNewsWire, Super Stock Screener, Micro Cap Daily, Marketbeat, 4-Traders, Market Screener, Zacks, StreetWise Reports, Stockhouse, Trading View, Capital Cube, Dividend Investor, Simply Wall St, Street Insider, Wallet Investor, and Real Investment Advice reported beforehand on Relmada Therapeutics, Inc. (RLMD), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A clinical-stage company, Relmada Therapeutics, Inc. is developing novel therapies for the treatment of central nervous system (CNS) diseases. The Company's lead program is dextromethadone (REL-1017). This is an N-methyl-D-aspartate (NMDA) receptor antagonist. Relmada Therapeutics lists on the OTC Markets Group's OTCQB. The Company is headquartered in New York, New York.

NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with an array of cognitive, neurological and behavioral symptoms. Relmada Therapeutics is targeting major advances in the treatment of CNS disorders.

REL-1017 (dextromethadone), the novel NMDA receptor antagonist, is in Phase 2 clinical testing for the treatment of depression, and preclinical development for Rett syndrome and other indications. REL-1017 is the Company's most-advanced new chemical entity. As a single isomer of racemic methadone, d-Methadone has been shown to possess NMDA receptor antagonist properties with almost no opioid activity or ketamine-like toxicities at the expected therapeutic doses.

Relmada Therapeutics' product candidates also include REL-1015 (LevoCap ER). REL-1015 is a novel version of a proven drug product. REL-1015 is an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol that is pharmacologically differentiated from morphine, oxycodone, and other strong opioids for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

Another product candidate is REL-1028 (BuTab). A novel version of a proven drug product, REL-1028 represents novel oral formulations of modified release buprenorphine undergoing development for chronic pain and opioid dependence indications.

Relmada also has its MepiGel (REL-1021) product candidate. A novel version of a proven drug product, MepiGel (REL-1021) is a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, including painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy.

Last week, Relmada Therapeutics announced that results of its N-methyl-D-aspartate receptor (NMDAR) antagonist REL-1017 (dextromethadone) single ascending dose and multiple ascending dose studies were accepted for publication in the peer reviewed Journal of Clinical Psychopharmacology. REL-1017 is presently in a Phase 2 study in individuals with major depressive disorder (MDD) who have not responded to traditional antidepressants. The design of the Phase 2, multicenter, randomized, double-blind, placebo-controlled, three arm study is to assess the safety, tolerability, and antidepressant effect of REL-1017 at two doses (25 mg QD and 50 mg QD) as an adjunctive therapy in the treatment of patients diagnosed with major depressive disorders.

Relmada Therapeutics, Inc. (RLMD), closed Wednesday's trading session at $1.91, up 4.95%, on 24,021 volume with 47 trades. The average volume for the last 3 months is 22,348 and the stock's 52-week low/high is $0.80/$2.01.

chart

Appliqate, Inc. (APQT)

Penny Stock Hub, Valuespectrum, Stockwatch, Market News Desk, InvestorsHub, Wallet Investor, GuruFocus, Dividend Investor, MarketWatch, GlobeNewswire, Stockhouse, Stockopedia, Trading View, Seeking Alpha, OTC Markets, and Interactive Brokers reported earlier on Appliqate, Inc. (APQT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets, Appliqate, Inc. operates as a marketing and technology company. It concentrates on text message marketing and loyalty rewards via text marketing. The Company offers a broad range of products. It engages customers by way of digital marketing. A Wyoming Corporation, Appliqate has its corporate headquarters in Draper, Utah.

The Company serves customers in the United States. In essence, Appliqate is an innovative new tool a business can use to contact their customers and keep their business fresh in their mind via Appliqate's Text Marketing Campaigns.

Appliqate's campaigns include Text Marketing; Bounceback; Vote; Trivia; Feedback; Text to Win; Spend Tracking; and Punch Card. For example, a Bounceback campaign permits a business to set up a keyword and build a database list of clients that have requested information. A Feedback campaign allows a business or organization to collect information from a client or group of clients.

Last month, Appliqate officially declared the successful launch of Onlichain. This is its blockchain accelerator business model. Together with this launch, Appliqate announced the appointment of technology entrepreneur, Mr. Darren Olayan, to spearhead the Onlichain business.

Via the acquisition of certain assets, Appliqate will provide founders with a full-stack, "idea to exit" blockchain business ecosystem. Through applying unique technology, an international talent pool, aligned capital, and a new exponential mindset, Appliqate can offer a platform that lessens risk, increases positive outcomes for start-ups, opens opportunities for entrepreneurs worldwide, and provides transparency and liquidity to entrepreneurs and their investors.

Additionally, last month, Appliqate announced it acquired a minority stake in Utah-based NUI Social (Nui). Furthermore, Appliqate acquired ownership of its digital wallet assets and intellectual property (IP). Established in 2017, NUI has greater than 300,000 trained sales reps. The NUI sales rep program provides people the opportunity to earn money through bringing exposure to digital applications on an assortment of platforms.

Moreover, the equity and asset purchase bring a strategic partnership, permitting NUI members to apply for the 88,572 person speciality blockchain sales force (Appliqate Affiliates), Appliqate is recruiting and training to launch more blockchain companies. This partnership allows Appliqate to promote blockchain products with reps specifically educated in blockchain while at the same time taking advantage of the large NUI network.

The Appliqate platform will help speed up the growth of companies centered on blockchain. The platform will also create awareness of those companies by members of the worldwide blockchain and cryptocurrency community.

Appliqate, Inc. (APQT), closed Wednesday's trading session at $2.526, up 12.77%, on 1,000 volume with 6 trades. The average volume for the last 3 months is 1,237 and the stock's 52-week low/high is $0.029/$2.549.

chart

UEX Corporation (UEXCF)

Equity Clock, Investing News, AASTOCKS, Wolcott Daily, Morningstar, Seeking Alpha, GuruFocus, OTC Markets, Barchart, Geology for Investors, Stockhouse, Stockwatch, MarketWatch, Market Screener, Barron's, Junior Mining Network, OTC Dynamics, and Wallet Investor reported previously on UEX Corporation (UEXCF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

UEX Corporation is a junior exploration company with a varied portfolio of projects in Saskatchewan's Athabasca Basin. Since its establishment, the Company has made major advancements in the discovery and development of existing and new uranium deposits in the Athabasca Basin. UEX is based in Saskatoon, Saskatchewan. The Company also has a satellite office in Vancouver, British Columbia.

UEX is involved in 19 uranium projects, including eight that are 100 percent owned and operated by UEX, one joint venture with Orano Canada, Inc. (Orano) and ALX Uranium Corp. (ALX) that is 50.1 percent owned by UEX and is under option to and operated by ALX, and also eight joint ventures with Orano, one joint venture with Orano and JCU (Canada) Exploration Company Limited that are operated by Orano, and one project (Christie Lake), that is 60 percent owned by UEX with JCU (Canada) Exploration Company Limited which is operated by UEX.

UEX's underpinning is considerable existing uranium resources. Additionally, the Company is exploring the West Bear Cobalt-Nickel Prospect via its 100 percent owned subsidiary CoEx Metals Corporation. The West Bear Project was earlier part of UEX's Hidden Bay Project. It contains the West Bear Cobalt-Nickel Prospect and the West Bear Uranium Deposit.

UEX is also increasing its resources at Christie Lake. The new Orora Discovery tested the Company's first identified new target on this project. Overall, UEX has a large inventory of historical mineralized holes that can undergo follow up to make new discoveries. Fundamentally, UEX's emphasis is on growing Christie Lake Uranium and enhancing Shareholder value through Cobalt.

UEX has received written confirmation from JCU (Canada) Exploration Company Limited acknowledging that UEX has increased its interest in the Christie Lake Uranium Project to 60 percent. UEX made the latest $1 million property payment to JCU and completed the 2018 exploration work commitments under the Christie Lake Option Agreement before the January 1, 2019 deadline. As a result, its ownership interest in the Christie Lake Joint Venture has increased from 45 percent to 60 percent effective November 13, 2018.

Last month, UEX announced that drilling started on its 100 percent owned West Bear Property with the goal of expanding the high-grade West Bear Co-Ni Deposit. The 2019 winter exploration program will consist of about 17,000 m of drilling in roughly 110-160 holes employing two drill rigs. At first, this program will concentrate on extending high-grade cobalt mineralization along strike to the west.

Last week, UEX announced the first tranche of assay results from the winter drilling program on its West Bear Property in the eastern Athabasca Basin of northern Saskatchewan. So far, UEX has completed 42 holes of this winter's exploration program. Assay results have been received for the first five holes of the winter program. Cobalt mineralization was encountered in all five holes. The strike length of the West Bear Deposit has been increased from 250 m to 400 m. 

UEX Corporation (UEXCF), closed Wednesday's trading session at $0.133, up 3.58%, on 17,000 volume with 2 trades. The average volume for the last 3 months is 33,619 and the stock's 52-week low/high is $0.10/$0.2593.

chart

DiaMedica Therapeutics, Inc. (DMAC)

Penny Stock Hub, Stockhouse, GuruFocus, Marketwired, Zacks, OTC Markets, Barchart, Business Insider, StreetInsider, MarketWatch, The Street, and WeeklyHub reported previously on DiaMedica Therapeutics, Inc. (DMAC), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

DiaMedica Therapeutics, Inc. concentrates on improving the lives of patients with neurological and kidney diseases associated with low KLK1 levels. The Company is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with a focus on neurological and kidney diseases. A clinical stage biopharmaceutical company, DiaMedica Therapeutics is headquartered in Minneapolis, Minnesota.

DiaMedica is developing DM199. This is a recombinant (synthetic) human protein for patients suffering from neurological and kidney diseases. DM199 has undergone clinical testing that demonstrates its exceptional safety as a potential treatment for an array of disorders. The Company is positing DM199 for the treatment of diabetic nephropathy and post-insult treatment from acute ischemic stroke (AIS).

DiaMedica Therapeutics is presently conducting a clinical trial designed to identify a dose of DM199 that is comparable to the human urinary and porcine approved versions in Asia. The results of the study will direct dosing for Phase II and Phase III clinical trials.

Furthermore, the Company has identified chronic kidney disease (CKD) caused by Type 1 diabetes as the primary indication for its first kidney disease trial. It announced in February of 2018 the first patient enrollment, at the Royal Melbourne Hospital, Melbourne Australia, in its Phase 2 REMEDY trial assessing the safety, tolerability and markers of therapeutic efficacy of DM199 (recombinant human KLK1) in patients suffering from acute ischemic stroke.

Ahon Pharmaceutical Co Ltd. (Ahon Pharma), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd, (Fosun Pharma) and DiaMedica Therapeutics have entered into a license and collaboration agreement. This agreement allows Ahon Pharma to have exclusive rights to develop and commercialize DM199 for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Fosun Pharma is one of China's largest pharmaceutical firms.

In January, DiaMedica Therapeutics announced that the U.S. Food and Drug Administration (FDA) accepted the Company's Investigational New Drug application (IND) for the initiation of a Phase Ib clinical trial of DM199 in patients with moderate or severe Chronic Kidney Disease (CKD) caused by Type I or Type II diabetes. The multi-site clinical study will enroll 32 subjects to assess DM199 safety, tolerability and drug levels (pharmacokinetics) in this specific population. This study will enroll subjects over a 12 day period. Moreover, it will include other end points that include renal biomarkers.

In addition, last month, DiaMedica Therapeutics announced the publication of a paper titled  "Human Tissue Kallikrein In The Treatment Of Acute Ischemic Stroke" in the peer reviewed journal, Therapeutic Advances in Neurological Disorders (TAND). The paper summarizes the mechanistic rationale for using KLK1 to treat patients with acute ischemic stroke (AIS). It summarizes human preclinical and clinical data supporting the hypothesis that KLK1 treatments may improve outcomes after AIS.

Co-author Todd Verdoorn, PhD., Chief Scientific Officer of DiaMedica Therapeutics, said, "DiaMedica is committed to providing helpful information to healthcare professionals and their patients regarding novel, experimental treatment strategies that may improve microvascular circulation and stroke. This paper, which reviews the published information about KLK1 and AIS, further supports the rationale for our ongoing Phase II REMEDY Clinical Trial."

DiaMedica Therapeutics, Inc. (DMAC), closed Wednesday's trading session at $3.41, up 2.71%, on 42,944 volume with 177 trades. The average volume for the last 3 months is 51,801 and the stock's 52-week low/high is $0.2588/$6.53.

chart

Micromem Technologies, Inc. (MMTIF)

MarketWatch, Penny Stock Tweets, Infront Analytics, Equity Clock, InvestorsHub, SmallCapVoice, Dividend Investor, last10k, Xtremepicks, OurHotStockPicks, GuruFocus, Wallet Investor, Stockhouse, Morningstar, Stock Stars, Trading View, PennyStocks24, Capital Cube, Investors Hangout, and Pink Investing reported earlier on Micromem Technologies, Inc. (MMTIF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Micromem Technologies, Inc. is a leader in viable Sensor Technology and MRAM (Magnetoresistive Random Access Memory). At present, the Company is focused on magnetic sensor applications via its wholly-owned subsidiary, Micromem Applied Sensor Technologies, Inc. (MAST, Inc.). OTCQB-listed, Micromem Technologies is based in Toronto, Ontario. The MAST, Inc. subsidiary is based in New York, New York.

Micromem's technologies and solutions include surface functionalization of magnetic nanoparticles; nanoparticle detection platforms to sub-ppb detection levels; customized integration of NEMS/MEMS sensor platforms; magnetic sensor solutions; and sensor-based analytical solution platforms. Technologies and solutions also include structural integrity sensors; wireless suib-surface power solutions; asset protection sensor platforms; and energy storage solutions.

Micromem Technologies designs, develops and provides sensors specific to industry needs. The MAST subsidiary centers on developing and marketing the delivery of inventive magnetic sensor applications in industries including Defense, Life Sciences, Automotive, Consumer, and Mining. MAST develops MEMS/NEMS solutions through combining disparate sensor modalities to create solutions for clients' problems.

MAST works closely with its clients during development to ensure a smooth transfer to their production facility. MAST is not a product company.

Concerning Energy Storage Solutions, MAST, working together with an energy storage company and a top U.S. utility, is providing sensor technology and overall system and product integration management for the practical realization of a new energy storage system. This system will enable lower costs than building new power generating plants.

Pertaining to its Magnetic Nanoparticle Detection Platform, MAST, working with a leader in the oil industry, has developed an instrument that detects breakthrough water in production oil wells through magnetic and optical sensor techniques.

This week, Micromem Technologies, via Micromem Applied Sensor Technologies, Inc. (MAST), announced an update on the status of the ATRA 171 project it has been developing over the last 5 years with its oil company partner, Chevron Corporation (NYSE: CVX). With this agreement, the continuing pilot project is proceeding through on site well evaluation. Also, the commercialization plans for this technology are progressing.

Micromem Technologies, Inc. (MMTIF), closed Wednesday's trading session at $0.0338, up 2.42%, on 133,334 volume with 11 trades. The average volume for the last 3 months is 229,940 and the stock's 52-week low/high is $0.0214/$0.1571.

chart

Nautilus Minerals, Inc. (NUSMF)

OTC Markets, PennyStockTweets, Stockhouse, Equities, Marketwired, InvestorsHub, Barchart, Junior Mining Network, The Street, MarketWatch, and YCharts reported previously on Nautilus Minerals, Inc. (NUSMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Nautilus Minerals, Inc. is the first company to explore the ocean floor for polymetallic Seafloor Massive Sulphide (SMS) deposits. Nautilus is developing a production system utilizing existing technologies adapted from the offshore oil and gas industry, dredging and mining industries to enable the extraction of these high-grade SMS systems on a commercial scale.

Nautilus Minerals has offices in Brisbane, Australia; Canada; and in Kavieng, New Ireland, Papua New Guinea, and Nuku'alofa, Tonga, South Pacific.

A seafloor resource exploration business, Nautilus explores and develops the ocean floor for copper, gold, silver, and zinc SMS deposits. Furthermore, the Company explores for manganese, nickel, copper, and cobalt nodule deposits. Nautilus has its copper-gold project named Solwara 1. It is under development in the territorial waters of Papua New Guinea (PNG).

The Solwara 1 deposit sits on the seafloor at a water depth of about 1600 meters. Solwara 1 contains a copper grade of approximately 7 percent. This compares with land-based copper mines, where the copper grade today averages 0.6 percent.

Gold grades of substantially more than 20 g/tonne have been recorded in some intercepts at Solwara 1. The average grade is roughly 6 g/tonne. Moreover, the Company holds highly prospective exploration acreage in the western Pacific (granted and under application), and in international waters in the Central Pacific.

Nautilus Minerals is currently negotiating the terms of an agreement with arm's length third parties. This would involve the establishment of a new joint venture company (the Vessel JV) to be owned by the third parties and Nautilus' subsidiary, Nautilus Minerals Niugini Limited (NMN).

The purpose of the Vessel JV would be to fund the acquisition of the Production Support Vessel (PSV) that Nautilus had previously arranged to be obtained through MAC Goliath Pte Ltd (MAC) and the integration expenses of installing the mining equipment on the PSV. The Vessel JV would own and operate the fully integrated PSV.

Yesterday, Nautilus Minerals announced that it and Deep Sea Mining Finance Ltd. agreed to extend the maturity date of the existing secured loan facility that is currently due on February 8, 2019, for 28 days ending on March 8, 2019.

Nautilus continues to seek short and long term funding solutions. This is while assessing its options, including different restructuring options. Negotiations with various third parties continue.

Nautilus Minerals, Inc. (NUSMF), closed Wednesday's trading session at $0.03, up 50.00%, on 5,030 volume with 2 trades. The average volume for the last 3 months is 58,722 and the stock's 52-week low/high is $0.00009/$0.1869.

chart

Rezolute, Inc. (RZLT)

Spotlight Growth, Emerging Growth, MarketWatch, Dividend Investor, Market Screener, OTC Markets, Simply Wall St, GuruFocus, Street Insider, Investing Online, The Street, Stockopedia, Morningstar, InvestorsHub, 4-Traders, Barchart, last10k, Stockhouse, YCharts and Wallet Investor reported earlier on Rezolute, Inc. (RZLT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rezolute, Inc. is a clinical stage biopharmaceutical company headquartered in Louisville, Colorado. It specializes in the development of innovative drug therapies for metabolic and orphan diseases. The Company formerly went by the name AntriaBio, Inc. It changed its corporate name to Rezolute, Inc. in December of 2017. Rezolute's shares trade on the OTC Markets Group's OTCQB.

Rezolute is advancing a divers pipeline. This pipeline includes RZ358 (Phase 2). This is an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy. In addition, the pipeline includes AB101 (Phase 1). This is a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management through reducing the therapeutic burden for patients and improving compliance.

The Company's pipeline also includes a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds. One is RZ402 targeting Diabetic Macular Edema (DME). The other is RZ602 targeting Hereditary Angioedema (HAE), an orphan indication.

Rezolute and XOMA Corporation have executed a license agreement. The agreement provides Rezolute with the exclusive international rights to develop and commercialize RZ358 (formerly XOMA 358) for Congenital Hyperinsulinism (CHI), an ultra-orphan indication. XOMA is a pioneer in the discovery, development, as well as licensing of therapeutic antibodies.

RZ358 is a first-in-class fully human monoclonal antibody. It counteracts the effects of elevated insulin via allosteric modulation of the insulin receptor. This makes it well-suited as a therapy for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI.

Last month, Rezolute announced that it entered into a $25 million preferred stock purchase agreement with two pharmaceutical companies that have elected to make a strategic investment in Rezolute. The investors include Handok, Inc., and Genexine, Inc., two premier publicly traded South Korean-based pharmaceutical companies. These two have a collective market capitalization of greater than $1.7 billion. With this agreement, each preferred share is priced at $5.00 and automatically converts into shares of Rezolute's common stock at an implied per share price of $0.22.

Rezolute's intention is to use the proceeds from this offering to advance its clinical programs. This includes initiating a Phase 2b clinical study for RZ358 in the U.S. and Europe; completing the required toxicology studies for RZ402 to enable the filing of an IND and initiation of clinical studies; and completing an ongoing Phase 1 study for AB101.

Rezolute, Inc. (RZLT), closed Wednesday's trading session at $0.185, off by 2.63%, on 12,500 volume with 6 trades. The average volume for the last 3 months is 5,695 and the stock's 52-week low/high is $0.09/$0.629.

chart

THC BioMed Intl. Ltd. (THCBF)

Stockhouse, Market Screener, Marketwired, Investors Hangout, Barchart, MarketWatch, Tip Ranks, Markets and Markets, Marketbeat, Insider Financial, Morningstar, InvestorsHub, YCharts, Wallet Investor, GuruFocus, and TradingView reported earlier on THC BioMed Intl. Ltd. (THCBF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

THC BioMed Intl. Ltd. is an ACMPR (Access to Cannabis for Medical Purposes Regulations) Licensed Producer and Canada's largest supplier of legal Cannabis Genetics. In addition, the Company produces and sells dried and fresh marijuana and cannabis oil for medical purposes. THC currently offers greater than two dozen different genetic strains for sale. The Company has the largest assortment of genetic strains available in Canada for home growers. THC BioMed is based in Kelowna, British Columbia.

On February 6, 2019, the  OTC Markets Group, Inc. (OTCM) announced that THC BioMed Intl Ltd. (OTCQX: THCBF) qualified to trade on the OTCQX® Best Market. THC BioMed upgraded to the OTCQX from the OTCQB® Venture Market.

The Company has its Clone Shipper acquisition. THC BioMed is laying the foundation in preparation for becoming the wholesaler of choice of live clones to the expected home growers' market. The patented design of the Clone Shipper 3.0 containers allows for an LED light to keep the clone in the growing vegetative stage for 12 to 24 hours during shipment. The Company is using the newly designed Clone Shipper 3.0 containers to ship live cannabis plants across Canada.

THC BioMed has created THC2GO Dispensaries. THC, by way of its wholly-owned subsidiary "THC2GO Dispensaries", began the application process to become a cannabis retailer in the Province of Manitoba. Moreover, THC2GO Dispensaries' intention is to apply for retail outlets in each Canadian province that permits private cannabis retail outlets.

THC BioMed has developed a cannabis beverage that imitates alcohol in that the uplifting and energizing effects of the cannabis is felt by the consumer in a short period of time. The Company believes that this beverage is a solution to a major problem with cannabis beverages and edibles, as present products cause fatigue and drowsiness. Production and sale of the beverage is not currently legal in Canada. It may become legal at a later date. THC BioMed intends to patent the formula.

THC BioMed announced in November 2018 that it received a Cannabis Act and Cannabis Regulations License from Health Canada on November 8, 2018. This is the new license under the Cannabis Act. It allows THC BioMed to grow, produce, as well as sell cannabis products on a large scale under the new regime.

This past December, THC BioMed announced that it made its first shipment of cannabis to the Province of Saskatchewan. The shipment included the Company's bestselling Cannabis strains in dried and pre-rolled forms.

Additionally, because of the high demand for its products, THC completed its fifth shipment of cannabis products to the Province of British Columbia. The shipment included THC BioMed's premium CBD Strain, branded THC CBD, and the Company's popular Atomical Haze strain.

THC BioMed Intl. Ltd. (THCBF), closed Wednesday's trading session at $0.22704, up 6.59%, on 44,222 volume with 34 trades. The average volume for the last 3 months is 70,895 and the stock's 52-week low/high is $0.1868/$1.05.

chart

WEED, Inc. (BUDZ)

Penny Stock Tweets, Stock Invest, Finance Registrar, Advanced Equity Research, Green Market Report, Tip Ranks, The Street, FXStreet, Market Screener, Wallet Investor, InvestorsHub, Micro Cap Daily, Equities, Barchart, Micro Small Cap, YCharts, 4-Traders, Capital Cube, Street Register, TradingView, Investor Place, Insider Financial, Stockhouse and MarketWatch reported previously on WEED, Inc. (BUDZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

WEED, Inc. is a multi-national, multi-faceted, vertically-integrated world class cannabis organization. The Company's commitment is to its worldwide goals and outreach across the complete spectrum of the cannabis industry to find treatments, therapies and medical cures using the Cannabaceae plant family. WEED has established WEED Israel (Cannabis) Ltd. as a wholly-owned subsidiary of WEED, Inc. (USA). OTCQB-listed, WEED has its head office in Tucson, Arizona.

WEED is structured as a holding company. It does business by way of its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to attain and promote its worldwide brand. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act. Furthermore, WEED meets all standards of international law for WEED, Inc. and its subsidiaries in foreign locales.

WEED has purchased a 4-acre property in La Veta, Colorado. This is where its wholly-owned subsidiary, Sangre AgroTech, is engaged in the previously announced 5-year, $15-plus million Cannabis Genomic Study. In association with the La Veta property, WEED received unanimous approval of the La Veta Town Council for a Commercial Redevelopment Permit to commence planned renovations and construction of the Bioscience Research Center for the operations of WEED's subsidiary, Sangre AgroTech, to convert the existing buildings into laboratory facilities required for Sangre to conduct its research, along with additional security and ground buildout.

Sangre AT, LLC, d/b/a Sangre AgroTech, has started a five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, through creating a global genomic classification of the entire plant. Through targeting cannabis-derived molecules, which stimulate the endocannabinoid system, Sangre AgroTech's research team plans to develop scientifically-valid and evidence-based cannabis strains for the production of disease-specific medicines. The aim of the research is to identify, collect, patent, and archive a collection of highly-active medicinal strains.

This past December WEED announced that its first of numerous cultivar DNA sequencing tests have been perfected and finalized. The Company's team of scientists is now going through the analytics evaluation. Reports are forthcoming.

Mr. Glenn E Martin, WEED's Chief Executive Officer, said, "During this time our team designed, tested, and refined standard operating procedures for efficient DNA isolation and sequencing of Cannabis genomes. Extensive bioinformatics analysis of repeatable and variable regions has been performed on newly-generated DNA sequencing data of 26 landrace cultivars and several publicly available genomes.''

WEED, Inc. (BUDZ), closed Wednesday's trading session at $0.92, up 4.55%, on 99,339 volume with 147 trades. The average volume for the last 3 months is 125,088 and the stock's 52-week low/high is $0.85/$6.34.

chart

The QualityStocks Company Corner

Hemptown USA

The QualityStocks Daily Newsletter would like to spotlight Hemptown USA.

Hemptown USA, headquartered in Central Point, Oregon, is a proven grower of full-spectrum hemp biomass grown using premium seed genetics that contain less than 0.3% THC and exceptionally high cannabinoid (CBD) content of up to 20%. The company's "soil to oil" methodology combines seasoned professionals working in hand-picked agricultural microclimates located in Oregon's famed Emerald Triangle, Kentucky and Colorado.

Hemptown has exclusive rights to 1 million rare CBG (cannabigerol) seeds genetically programmed to yield from 15% to 20% full-spectrum non-intoxicating cannabinoids. As a result of a long-standing relationship with the one of the world's most respected cannabis breeding companies – Oregon CBD Seeds – Hemptown is positioned to be a leading CBG producer in the U.S. in 2019 and beyond.

In 2018 Hemptown's harvest from its Oregon hemp farm was 150,000 pounds of full-spectrum biomass with CBD content hovering around 17%. 2018 harvest revenue expected to range from $8.1 million to $12.6 million. The company is scaling up operations in 2019 to meet market demands and projects it will reap over 1,000,000 pounds. By 2020, Hemptown projects potential revenues in the $100 million to $200 million range are possible once additional farming operations are at full strength.

Growth Strategy

By 2020, Hemptown anticipates it will have more than 3,000 acres in several states dedicated to hemp farming. Expansion plans include increasing in-house extraction capabilities to boost profit margins by providing additional CBD and CBG isolates and distillation services. Development of business-to-business channels as well as new products and formulations for the direct-to-consumer market, along with several strategic acquisitions, are also key to Hemptown's growth strategy.

Hemptown plans to expand distribution and growing operations globally through strategic partnerships and development of contracts with leading Fortune 500 brands in European markets. The company intends to grow its IP portfolio by developing a proprietary water-soluble cannabinoid delivery system. Not to be confused with water-compatibility, water-soluble cannabinoids combine seamlessly with other liquids, have a superior shelf life, and deliver dramatically increased efficacy to the consumer.

Branded Products

Hemptown's first in-house branded product line combines the inspiring strength found in the unbridled nature that surrounds the company's original hemp farm in the Siskiyou Klamath region of Oregon. Siskū is set to redefine the cannabinoid packaged goods space with an elegant look, clean feel and potent, reliable efficacy.

Custom product lines can also be created for any product manufacturer as Hemptown brings GMP and ISO accredited processing facilities online in 2019. Together with Oregon CBD Seeds and Hemptown's product sciences team, Hemptown will be able to create custom, proprietary full-spectrum CBD and CBG oils and pure isolates.

Management Team

Company Chairman Rod Wolterman founded Hemptown's Oregon operations in 2016. He has extensive experience in the cannabis sector having been active within the space since 1998. Wolterman has also acted as a private equity investor in numerous medical marijuana dispensaries and cultivation operations in southern California.

CEO John Cummings has over 20 years of experience in finance, marketing, sales and project management. He led the compliance and special projects efforts for Kings Garden, one of the largest vertically integrated operators in California. Cummings also spent a year in Europe launching the continent's first GMP and ISO-accredited cultivation and manufacturing facility.

Dr. Gordon Chiu is chief science officer for Hemptown USA. He has more than 15 years of combined domestic and international experience in biomedical, chemical, cosmetic, medical and technology industries. A graduate of Rensselaer Polytechnic Institute with a master's degree from Seton Hall University, Chiu is leading Hemptown's cannabinoid research team and is responsible for filing IP patents, specifically in the areas of water-solubility, bioavailability and peptide sequencing.


Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8), and how it is positioned to make an impact in the California market.

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $7.43, up 13.26%, on 586,806 volume with 535 trades. The average volume for the last 3 months is 125,045 and the stock's 52-week low/high is $0.769/$6.43.

Recent News

chart

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element (NASDAQ: NETE), a global technology and value-added solutions group, recently reported substantial financial growth in 2018. To view the full article, visit: http://nnw.fm/6ScYq.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

With an eye on emerging markets, Net Element is pursuing growth opportunities and footholds in a number of industries. The company’s most recent application of its technology is to the cannabis industry, which is paced to hit $591 million and could increase 40 times in the next four years. This rampant growth also creates heightened need for smooth transactions between merchants and consumers. Payment processing and compliance for the cannabis industry has become increasingly complex, and Net Element’s Unified Payments subsidiary is addressing the challenges by offering a compliant, seamlessly integrated payment solution that makes it simple to transact.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $5.78, up 2.12%, on 61,801 volume with 424 trades. The average volume for the last 3 months is 65,146 and the stock's 52-week low/high is $3.75/$10.60.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2018 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website approximately one day after the teleconference).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.50, up 1.45%, on 2,260 volume with 9 trades. The average volume for the last 3 months is 17,248 and the stock's 52-week low/high is $1.52/$4.10.

Recent News

chart

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) was featured today in the 420 with CNW by CannabisNewsWire. Ever since voters in Maine approved a ballot measure to legalize recreational marijuana in 2016, the state had never formulated rules to regulate the commercialization of adult-use cannabis even if residents were allowed to grow a limited number of cannabis plants soon after the midterm vote that paved the way for recreational marijuana. Two years later, the state has released its draft rules indicating how the recreational market will be regulated.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.49, up 0.68%, on 172,494 volume with 284 trades. The average volume for the last 3 months is 692,451 and the stock's 52-week low/high is $0.85/$2.04.

Recent News

chart

Geyser Brands Inc. (TSX.V: GYSR)

The QualityStocks Daily Newsletter would like to spotlight Geyser Brands Inc. (TSX.V: GYSR).

Geyser Brands (TSX.V: GYSR) this morning announced its engagement of the founder and CEO of Brandeavour Anthony Webb, brand expert and strategist, as its consultant of record for strategic branding and creative counsel. To view the full press release, visit: http://cnw.fm/m0Nxt.

Geyser Brands Inc. (TSX.V: GYSR) is a consumer healthcare company that builds and markets some of the world's most loved cannabis products and brands in the nutraceutical, cosmetics, food and beverage and pet sectors. Using its proprietary nanotechnology formulation, the company delivers creams, beverages, baked goods and tincture formulations with superior bioavailability and water solubility.

NanoFusion Technology

The efficacy of most hemp?products is restricted as the insoluble nature of the molecules prevents most of the product from permeating the skin or entering the body system. Geyser Brands solves this insolubility problem with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency.

Made with all-natural materials, NanoFusion technology offers an array of advantages: enhances penetration for deeper skin penetration; improves the transport of active ingredients for site-specific targeting; delivers active ingredients across cell membranes for release within the cell; provides longer shelf-life and stability of molecules.

Operations

Geyser Brands operates a 7,000-square-foot facility in Port Coquitlam, British Columbia, where its initial cannabis cultivation generated the first revenues out of the company's cultivation license granted in October 2018. Geyser Brands is approved as a licensed producer in compliance with Health Canada standards, which allows the company to pursue its processing and sales license. Obtaining this license will enable the company to extend its products and brands into the regulated Canadian cannabis market and directly to the consumer medical market.

Geyser Brands's integrated production chain and formulation lab develops innovative products using high-quality hemp and CBD for healthy lifestyle brands while its R&D lab produces product formulations designed to enhance bio-availability of hemp and CBD and shelf stability while maintaining all-natural ingredients and ensuring premium quality.

Geyser Brands will continue to seek opportunities to invest into the research and development of unique high-quality proprietary strains and technologies that target specific health-related conditions such as pain and inflammation reduction, insomnia, digestive issues and other commonly known ailments.

Growing Portfolio

Among the brand formulations in Geyser Brand's portfolio are:

  • Apothecary all-natural Hemp Terpene Pain Cream with optimal skin permeation
  • Prohibition Cold Brew Mocha designed with water soluble hemp molecules
  • Apothecary health products created to deliver fast-acting and high bioavailability in a spray formulation
  • Baked hemp infused pet products, designed to alleviate anxiety and pain, created with NanoFusion for dosage control

Management Team

Since 2014, Geyser Brands' CEO and Co-Founder Andreas Thatcher has been a principal at Rhizome Group, an entertainment company focused on building media IP through creative and market development. He previously was a founding partner at Rhizome Capital LLC, a U.S.-based media?investment?company specializing in marketing and distribution financing, and worked in the Investment Banking industry in?London and Toronto. Thatcher holds a master's degree in economics.

CFO Barry McKnight obtained his bachelor's degree from the University of British Columbia and is a Chartered Professional Accountant and?Certified Management Accountant registered in British Columbia. McKnight has over 20 years of experience as the principal of Barry D. McKnight Inc. He formerly was also a director of Indigo Sky Capital Corp. and has been the CFO and a director of the Company since 2016 and Corporate?Secretary of the Company since 2017.

Geyser Brands's Co-Founder Brad Kersch brings a strong business background with over 20 years of experience in?successful startups and working?with Fortune 500 companies. He spent his early years in the advertising and?marketing field and went on to form Hyperware, a clothing?company that sold branded clothing to retailers across Canada?before selling to clothing giant Ocean Pacific (OP). Kersch?became the president of Shoreline Studios, Canada's largest and?oldest?studio for film and TV. In 2014 he started Solace Management Group, a hemp product company focused on pet, cosmeceutical, and nutraceutical markets. As of February 2019, Geyser Brands signed a non-binding LOI to acquire Solace Management. Upon completing the proposed Solace acquisition, Geyser Brands intends to launch into the execution phase of its plan — to take its brands global through retail and digital direct-to-consumer experiences, launching its hemp-infused cannabis brands and products in the U.S., European Union, and Asia, and its CBD-infused line of products in jurisdictions where the therapeutic ingredient is legal.

Kuldip Gill, head of Geyser Brands' R&D program, has more than 35 years of experience in the cannabis industry. Gill built the largest manufacturing facility?in the lower mainland in Surrey, British Columbia, complete with R&D, analytical and quality control labs approved by both the FDA and Health Canada. He has to date created over 3,500 formulas, most notably Lakota pain relief gel. Gill's experience and proven track record is evident in the strongly marketable formulations he has developed and sold worldwide.

Geyser Brands Inc. (TSX.V: GYSR), closed the day's trading session at $0.85, up 6.25%, on 20,088 volume with 13 trades. The average volume for the last 3 months is 7,107 and the stock's 52-week low/high is $0.61/$0.80.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

SmallCapVoice.com, Inc. and Nightfood Holdings, Inc. (OTC QB: NGTF), a pioneering consumer goods brand development company that owns both Nightfood, Inc. and MJ Munchies Inc., announced today that the Company is featured in a new audio interview at SmallCapVoice.com, Inc.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed the day's trading session at $0.645, up 9.32%, on 165,475 volume with 91 trades. The average volume for the last 3 months is 554,803 and the stock's 52-week low/high is $0.16/$0.92.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech Inc. (OTCQB: ETST), a Florida-based biotechnology company focused on cannabis and cannabinoid research and development, nutraceuticals, pharmaceuticals and medical devices, is well-positioned to take advantage of the growing demand for cannabinoid products by offering the highest purity and quality cannabinoids on the market.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.60, up 1.69%, on 17,481 volume with 15 trades. The average volume for the last 3 months is 31,216 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

Premier provider of financial news and education for the Chinese-speaking community ChineseInvestors.com (OTCQB: CIIX) today announced that its CEO Warren Wang was featured in a new audio interview at SmallCapVoice.com. To listen to the audio interview, visit: http://nnw.fm/L4hUs. To view the full press release, visit: http://nnw.fm/zIez0.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.49, up 1.78%, on 89,339 volume with 48 trades. The average volume for the last 3 months is 73,198 and the stock's 52-week low/high is $0.365/$1.25.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (MCOA) is pleased to announce the appointment of Mr. Edward Manolos as an independent director. Mr. Manolos is one of the most accomplished pioneers in the medical marijuana industry, having opened the very first medical marijuana dispensary in Los Angeles County in 2004 called CMCA. He is also credited with starting Los Angeles' first medical marijuana farmers' market referred to as "The California Heritage Market," which attracted local and international media attention. Mr. Manolos has been a member of the Company's Strategic Advisory Board since 2016.Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how, in both Canada and the U.S., the number of retail stores and dispensaries has been exponentially growing since the end of 2018.

Marijuana Company of America Inc. (OTC: MCOA) (the "Company") are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0128, even for the day, on 5,204,983 volume with 263 trades. The average volume for the last 3 months is 11,760,962 and the stock's 52-week low/high is $0.01025/$0.049.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria CanPharm ULC, to provide Lexaria's patented DehydraTECHTM technology to a private California-based cannabis company for its utilization in certain cannabis-based beverages to be produced and sold in the states of California and Nevada.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.0175, off by 4.01%, on 125,878 volume with 133 trades. The average volume for the last 3 months is 133,624 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands Inc. (OTCQB:WLDFF) (CSE:SUN) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for private and public entities in the cannabis industry. To view the full publication, titled "The Cannabis Bonanza Has Just Begun," please visit: http://cnw.fm/4kiHL.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.5478, off by 2.26%, on 28,660 volume with 16 trades. The average volume for the last 3 months is 22,699 and the stock's 52-week low/high is $0.009/$1.139.

Recent News

chart

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

QMC Quantum Minerals Corp., (TSX.V: QMC) (FSE: 3LQ) (OTC PINK: QMCQF) ("QMC" or "the Company") is pleased to provide an update on the company's 100% owned Irgon Lithium Mine Project located within the prolific Cat Lake-Winnipeg River rare-element pegmatite field of S.E. Manitoba, which also hosts Cabot Corporation's nearby Tantalum Mining Corporation of Canada ("TANCO") rare-element pegmatite.

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.18, off by 5.31%, on 136,500 volume with 31 trades. The average volume for the last 3 months is 46,463 and the stock's 52-week low/high is $0.1155/$0.512.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (SGMD) was featured today in the 420 with CNW by CannabisNewsWire. Ever since voters in Maine approved a ballot measure to legalize recreational marijuana in 2016, the state had never formulated rules to regulate the commercialization of adult-use cannabis even if residents were allowed to grow a limited number of cannabis plants soon after the midterm vote that paved the way for recreational marijuana. Two years later, the state has released its draft rules indicating how the recreational market will be regulated.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.04176, off by 0.57%, on 828,960 volume with 81 trades. The average volume for the last 3 months is 1,297,477 and the stock's 52-week low/high is $0.039/$0.1975.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.